Loading
A phase 3 trial of Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer is a phase 3 interventional study registered as NCT07522151 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 874 participants planned, started 2026-05-07 and due to reach its primary completion in 2029-12. Interventions recorded: Adebrelimab plus S-1 and oxaliplatin and Adebrelimab blank preparation plus S-1 and oxaliplatin..
Shares Adebrelimab, Oxaliplatin, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Platinum agents, Monoclonal antibodies and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Jiangsu Hengrui Pharmaceuticals, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Oxaliplatin, Platinum agents, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Oxaliplatin, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.